SAN DIEGO, Feb. 27, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- MicroIslet, Inc. (AMEX:MII), a biotechnology company engaged in the development and commercialization of patented technologies in transplantation therapy for people with insulin-dependent diabetes, announced today that it filed on February 26, 2007 a plan with the American Stock Exchange (AMEX) outlining the actions it proposes to take to bring it into compliance with AMEX's continued listing standards relating to minimum stockholders' equity. MicroIslet previously announced that it had been informed that it was not in compliance with AMEX's continued listing standards relating to minimum stockholders' equity and was afforded the opportunity to submit a plan of compliance to the AMEX by February 26, 2007
